ClinicalTrials.gg
RecruitingNCT06347094PRE-CARE-DIETUpdated Nov 9, 2026

Precision Nutrition to Improve Cardiometabolic Health With Dietary (Poly)Phenols

An interventional study of Personalized Dietary Plan and Oral (Poly)phenol Challenge Test (OPCT) in Individual Variability in (Poly)Phenol Metabolism, Cardiometabolic Health and Personalized Dietary Intervention, sponsored by University of Parma. Recruiting at 2 sites in Italy. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Parma · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 9, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Obesity with a site in Italy — 99 open to participants now, 118 under way, 28 of them phase 3. Obesity · Italy.

Planned enrollment
52nd of 229
330 · median 90
Started
2024
with 34 others
No phase
157 of 342
42 open now
Primary completion
2027-02
later than 67 of 117 live
Registered
245th of 342
by date

Among the 342 studies in Obesity with a site in Italy, this one is the 52nd largest by planned enrollment of the 229 interventional ones that give a count, is one of 35 that started in 2024, is one of 157 with no phase, reaches primary completion later than 67 of the 117 other live ones, and was the 245th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

99 of the 342 studies in Obesity with a site in Italy are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Obesity with a site in Italy, or all of them as a file.
02

Study summary

This chronic study aims at assessing whether the effects of a personalized, plant-based diet rich in (poly)phenols on cardiometabolic health depend on the capability to metabolize dietary (poly)phenols, creating predictive models able to explain, at individual level, the cardiometabolic response. This study presents an observational part, for targeted recruitment and volunteers characterization, and an experimental part for the dietary and deep phenotyping.

Read the detailed description

The recruitment will be carried out to prospectively include 330 subjects belonging to two aggregate phenolic metabotypes following an Oral (Poly)phenol Challenge Test (OPCT), that will be compared in the intervention part (1:1). In the observational phase, eating habits and lifestyle data will be collected, and these will serve as a run-in for the experimental phase. In the experimental phase, two-thirds of the participants within each metabotype will be randomly allocated to the treatment arm: 50% increase in the (poly)phenol intake, with a minimum daily intake of 500 mg. Treatment allocation shifts minimally the dietary habits of treated participants to allow causal explanations. No changes in the (poly)phenol intake will be asked to the control arm, composed of one-third of the subjects in each metabotype. Blood pressure and heart rate will also be measured and anthropometric data collected. Information will be accessed on cardiometabolic risk scores, cardiometabolic health biomarkers, inflammatory markers, hormones, metabolism of food components, genetic polymorphisms, gut and saliva microbiota profile, etc., through the collection of saliva, urine, blood, and stool samples.

03

Conditions studied

  • Individual Variability in (Poly)Phenol Metabolism
  • Cardiometabolic Health
  • Personalized Dietary Intervention
  • Obesity

Browse trials for

Keywords

  • nutritional intervention study
  • personalized nutrition
  • cardiometabolic risk
  • obesity
  • (poly)phenols
  • metabotypes
  • inter-individual variability
  • food-gut-host interactions
  • predictive models
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (40-80 y.o.)
  • Non-clinically diagnosed for cardiometabolic diseases at baseline examination
  • At least one of the following risk factors: overweight or obese, central obesity (waist:hip ratio > 0.90 in males and > 0.85 in females or waist circumference ≥ 94 cm in males and ≥ 80 cm in females), hypertension (systolic BP > 130 or diastolic BP > 85 mm Hg), low high-density lipoprotein cholesterol levels (\< 40 mg/dL (1.03 mmol/L) in males, \< 50 mg/dL (1.29 mmol/L) in females), or elevated total cholesterol (≥ 200 mg/dL), low-density lipoprotein cholesterol (≥ 130 mg/dL (4.1 mmol/L)), triglyceride (> 150 mg/dL (1.7 mmol/L)), fasting glucose (> 100 mg/dL (5.6 mmol/L)) levels, or microalbuminuria (urinary albumin excretion ratio ≥ 20 μg/min or albumin:creatinine ratio ≥ 30 mg/g). In addition, it is necessary that the weight has been stable for at least 3 months. Similarly, concerning an ongoing therapy with medication or supplements, these must have been in use for at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • \< 18.5 or > 40.0 kg/m²
  • Past cardiovascular events and metabolic diseases including diabetes
  • Inflammatory bowel diseases or gastro-intestinal surgery (other than appendectomy)
  • Cholecystectomy within the past 5 years
  • Renal or hepatic diseases
  • Levels of estimated Glomerular Filtration () \< 60 mL/min/1.73 m²
  • (AST)/alanine aminotransferase (ALT) 2.5 times the
  • Immunodeficiency or diseases (other than well-compensated hypothyroidism)
  • Mental disorders
  • Hormone therapy (other than that used for hypothyroidism, birth-control or menopause symptoms)
  • Antibiotic therapy within the last month before the study
  • Food allergies associated with the consumption of plant foods or foods that will be provided in the study
  • Difficulties or major inconveniences in changing dietary habits or adhering to a plant-based Mediterranean-type diet
  • Presence of chewing or swallowing disorders
  • Pregnancy or lactation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Metabotype X, Treatment

    Subjects belonging to a specific aggregate phenolic metabotype (X) to which a diet with an increase of 50% in the actual (poly)phenol intake will be given, through personalized dietary plans.

    Other: Personalized Dietary Plan · Dietary Supplement: Oral (Poly)phenol Challenge Test (OPCT)

  • Experimental
    Metabotype X, Control

    Subjects belonging to a specific aggregate phenolic metabotype (X) to which general dietary recommendations for a healthy diet will be given.

    Dietary Supplement: Oral (Poly)phenol Challenge Test (OPCT) · Other: General Dietary Advice

  • Experimental
    Metabotype Y, Treatment

    Subjects belonging to a specific aggregate phenolic metabotype (Y) to which a diet with an increase of 50% in the actual (poly)phenol intake will be given, through personalized dietary plans.

    Other: Personalized Dietary Plan · Dietary Supplement: Oral (Poly)phenol Challenge Test (OPCT)

  • Experimental
    Metabotype Y, Control

    Subjects belonging to a specific aggregate phenolic metabotype (X) to which general dietary recommendations for a healthy diet will be given.

    Dietary Supplement: Oral (Poly)phenol Challenge Test (OPCT) · Other: General Dietary Advice

Interventions

  • OtherPersonalized Dietary Plan

    Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet

  • Dietary supplementOral (Poly)phenol Challenge Test (OPCT)

    Nutritional challenge with standardized (poly)phenol-rich tablets

  • OtherGeneral Dietary Advice

    Prescription of balanced dietary plans

06

What researchers measure

Primary outcomes

  1. Assessing the effect of a (poly)phenol-rich diet on 10-year cardiovascular risk: Systematic Coronary Risk Estimation

    Assessing the effect of a (poly)phenol-rich diet on 10-year risk of cardiovascular disease using the Systematic Coronary Risk Estimation (SCORE2) for volunteers aged between 40 and 69 years, considering different aggregate phenolic metabotypes. Interpretation of the result depends on the patient's age as the cut-off risk levels are numerically different for various age groups: low-moderate Cardiovascular Disease (CVD) risk (\< 2.5% for \< 50 years; \< 5% for 50-69 years), high CVD risk (2.5% to \< 7.5% for \< 50 years; 5% to \< 10% for 50-69 years), very high CVD risk (≥ 7.5% for \< 50 years; ≥ 10% for 50-69 years).

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  2. Assessing the effect of a (poly)phenol-rich diet on 10-year cardiovascular risk: Systematic Coronary Risk Estimation-Older Persons

    Assessing the effect of a (poly)phenol-rich diet on 10-year risk of cardiovascular disease using the Systematic Coronary Risk Estimation-Older Persons (SCORE2-OP) for volunteers aged between 70 and 89 years, considering different aggregate phenolic metabotypes. Interpretation of the result depends on the patient's age as the cut-off risk levels are numerically different for various age groups: low-moderate CVD risk (\< 7.5% for ≥ 70 years), high CVD risk (7.5% to \< 15% for ≥ 70 years ), very high CVD risk (≥ 15% for ≥ 70 years).

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

Secondary outcomes

  1. Anthropometric measurements: weight, height and body mass index

    Weight (measured in kilograms) and height (measured in meters) will be assessed using a balance and a stadiometer, respectively. These measures will be combined to report the Body Mass Index (BMI) using the following formula: kg/m\^2.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  2. Anthropometric measurements: waist and hip circumferences detection

    Waist circumference (measured in centimeters) and hip circumference (measured in centimeters) will be assessed using an inelastic meter. These measures will be combined to report waist-to-height ratio and waist-to-hip ratio using the following formulas: waist circumference (cm)/height (cm) and waist circumference (cm)/hip circumference (cm), respectively.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  3. Body composition: bioelectrical impedance analysis

    Body composition estimation will be assessed using a bioelectrical impedance analysis (BIA). It is a tool that provides an estimate of qualitative and quantitative analysis of body composition and distribution.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  4. Blood pressure

    Systolic and diastolic blood pressure measured in millimeters of mercury (mmHg) of each volunteer will be obtained after a 5-min rest in a seated position.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  5. Heart rate

    Heart rate, measured in beats per minute (bpm) of each volunteer will be obtained after a 5-min rest in a seated position.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  6. Biomarkers of cardiometabolic health: hematochemical and urine analysis

    Blood samples will be collected for the assessment, measured in milligrams per deciliter, of total cholesterol (mg/dL), HDL-cholesterol (mg/dL), triglycerides (mg/dL), glucose (mg/dL), lipoprotein a (mg/dL), apolipoprotein A1 (mg/dL), apolipoprotein B (mg/dL) and uric acid (mg/dL). Non-HDL cholesterol, triglyceride/glucose index, triglyceride/waist circumference index, and ApoB/ApoA ratio will be estimated using the reference formula.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  7. Biomarkers of cardiometabolic health: alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase

    Blood samples will be collected for the assessment, measured in enzymatic unit activity per liter, of alanine aminotransferase (U/L), aspartate aminotransferase (U/L) and gamma glutamyl transferase (U/L).

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  8. Biomarkers of cardiometabolic health: homocysteine

    Homocysteine, measured in milligrams per liter, will be assessed from serum samples.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  9. Biomarkers of cardiometabolic health: insulin

    Insulin, measured in micro Insulin Units per milliliter, will be assessed from plasma samples.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  10. Biomarkers of cardiometabolic health: glycated hemoglobin and glycated albumin

    Blood samples will be collected for the assessment, measured in percentage of total hemoglobin, of glycated hemoglobin (HbA1c (%)) and glycated albumin (%).

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  11. Biomarkers of cardiometabolic health: quantitative insulin-sensitivity check index

    Fasting insulin sensitivity will be estimated through the quantitative insulin-sensitivity check index (QUICKI) - using the following formula: 1/log(fasting insulin (uUI/mL)) + log(fasting glucose (mg/dL)) -, McAuley's index, and the metabolic score for insulin resistance (METS-IR).

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  12. Biomarkers of cardiometabolic health: homeostasis model assessment beta-cell function

    Insulin secretion capacity will be estimated through the homeostasis model assessment beta-cell function (HOMA-β) index using the following formula: 360 \* insulin (uUI/mL)/glucose (mg/dL) - 55.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  13. Biomarkers of cardiometabolic health: homeostasis model assessment of insulin resistance

    Insulin resistance will be estimated through the homeostasis model assessment of insulin resistance (HOMA-IR) index using the following formula: glucose (mg/dL) \* insulin (uUI/mL)/82 \* 7.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  14. Inflammatory status

    Plasma samples will serve to determinate the inflammatory status monitoring specific cytokines (Tumor Necrosis Factor α, InterLeukin-1β, InterLeukin-6, InterLeukin-8, InterLeukin-10, and Monocyte Chemoattractant Protein-1), adhesion molecules (Vascular cell adhesion protein-1, Intercellular Adhesion Molecule-1, E-selectin), and high sensitivity C reactive protein (hsCRP), using a customized magnetic bead-based multiplex assays.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  15. Risk prediction scores: Framingham General Cardiovascular Risk Score - 10-years

    The Framingham General Cardiovascular Risk Score (FRS) - 10 years will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. The FRS estimates the 10-years risk of manifesting clinical CVD (CAD, Stroke, cardiac death). Risk is considered low if the FRS is less than 10%, moderate if it is 10% to 19%, and high if it is 20% or higher.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  16. Risk prediction scores: Framingham General Cardiovascular Risk Score - 30-years

    The Framingham General Cardiovascular Risk Score (FRS) - 10 years will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. The FRS estimates the 30-years risk of manifesting clinical CVD (CAD, Stroke, cardiac death). Risk is considered low if the FRS is less than 12%, moderate if it is 12% to 40%, and high if it is 40% or higher.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  17. Risk prediction scores: Hard Coronary Heart Disease - 10-years risk

    The Framingham Heart Study Primary Risk Functions for Hard Coronary Heart Disease (HCHD) 10-year risk will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. The HCHD estimates the 10-years risk of manifesting myocardial infarction or coronary death. Risk is considered low if the HCHD is less than 1%, moderate if it is 1%, and high if it is 2% to 11% for female; risk is considered low if the HCHD is less than 1%, moderate if it is 1%, and high if it is 2% to 25% for male.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  18. Risk prediction scores: First Coronary Heart Disease - 2-years risk

    The Framingham Heart Study Primary Risk Functions for First Coronary Heart Disease (2-years risk) will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. This risk score estimates the 2-years risk of manifesting a first event of myocardial infarction or coronary death. Risk is considered low if the score is less than 0%, moderate if it is 0% to 1%, and high if it is 1% or higher for female; risk is considered low if the score is less than 0%, moderate if it is 0% to 1%, and high if it is 1% to 6% for male.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  19. Risk prediction scores: Framingham Heart Study for Diabetes

    The Framingham Heart Study Primary Risk Functions for Diabetes will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. This risk score estimates the risk of manifesting type 2 diabetes mellitus (fasting blood glucose at or above 126 mg/dL) in 8 years. Risk is considered low if the score is less than 3% and high if it is 4% to 18%.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  20. Risk prediction scores: Framingham Heart Study for Hypertension

    The Framingham Heart Study Primary Risk Functions for Hypertension will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. This risk score estimates the risk of incidence of hypertension. Risk is considered low if the score is less than 5%, moderate if it is 5% to 10%, and high if it is higher than 10%.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  21. Risk prediction scores: Framingham Heart Study for Stroke

    The Framingham Heart Study Primary Risk Functions for Stroke will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. This risk score estimates the 10-year probability of stroke. The risk score is given as a percentage and higher percentage values correspond to an increased risk of stroke.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  22. Risk prediction scores: Framingham Heart Study for Fatty Liver Disease

    The Framingham Heart Study Primary Risk Functions for Fatty Liver Disease will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. This risk score estimates the 10-year risk of CVD events in individuals with non-alcoholic fatty liver disease (NAFLD) The risk score is given as a percentage and higher percentage values correspond to an increased risk of CVD events.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  23. Risk prediction scores: Atherosclerotic Cardiovascular Disease

    The Atherosclerotic Cardiovascular Disease (ASCVD) risk will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. It is an index of the 10-year risk of having a cardiovascular problem, such as a heart attack or stroke. The ASCVD risk score is given as a percentage and there are four groupings: a 0 to 4.9 percent risk is considered low; a 5 to 7.4 percent risk is considered borderline; a 7.5 to 20 percent risk is considered intermediate; a greater than 20 percent risk is considered high.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  24. Risk prediction scores: QRESEARCH risk estimator version 3

    The QRESEARCH risk estimator version 3 (QRISK3®) will be assessed to understand their relationship with the aggregate phenolic metabotypes observed. It is an index of the 10-year risk of having a cardiovascular problem, such as a heart attack or stroke. The QRISK3® risk score is given as a percentage and there are three groupings: low risk if the QRISK3 score of less than 10%; moderate risk if the QRISK3 of 10-20%; high risk if the QRISK3 score of more than 20%.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  25. Risk prediction scores: QDiabetes Score

    The QDiabetes Score® will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. QDiabetes® is a validated tool which predicts the absolute risk of developing type 2 diabetes in the next 10 years. The QDiabetes Score® risk score is given as a percentage: high risk is defined for QDiabetes of 5.6% or greater, while it is low for lower values.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  26. Risk prediction scores: Finnish Diabetes Risk Score

    The Finnish Diabetes Risk Score (FINDRISC) will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. FINDRISC is a prediction tool to identify patients at risk of developing diabetes. A risk score of 0-14 points indicates a low to moderate risk of diabetes (1-17% chance of diabetes over 10 years). A risk score of 15-20 points indicates a high risk of diabetes (33% chance of diabetes over 10 years). A risk score of \>20 points indicates a very high risk of diabetes (50% chance of diabetes over 10 years).

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  27. Risk prediction scores: Cuore Project - Calculating the individual risk score

    The Calculating the individual risk score (Italian CVD risk score) will be assessed to understand the relationship with the aggregate phenolic metabotypes observed. Six cardiovascular risk categories were constructed, called MCV (from I to VI): the MCV risk category indicates how many persons out of 100 with the same characteristics will fall ill over next 10 years. Risk is considered: below 5% for MCV I; 5% to 10% for MCV II; 10% to 15% for MCV II; 15% to 20% for MCV IV; 20% to 30% for MCV V; over 30% for MCV VI

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  28. Evaluation of adherence to healthy and sustainable dietary models: the Healthy Eating Index

    Adherence to healthy dietary patterns will be assessed by the Healthy Eating Index (HEI), which is a measure of diet quality used to assess how well a set of foods aligns with key recommendations and dietary patterns. The HEI uses a scoring system from 0 to 100. There are two groupings: 1) "Adequacy components" represent the food groups, subgroups, and dietary elements that are encouraged and for these components, higher scores reflect higher intakes, because higher intakes are desirable; 2) "Moderation components" represent the food groups and dietary elements for which there are recommended limits to consumption and for moderation components, higher scores reflect lower intakes, because lower intakes are more desirable.

    Time frame: Visit 2 (after 4 weeks from the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  29. Evaluation of adherence to healthy and sustainable dietary models: Italian Mediterranean Index

    Adherence to Italian Mediterranean diet will be assessed by the Italian Mediterranean Index. The score is calculated from intake of 11 items: high intakes of six typical Mediterranean foods (pasta, typical Mediterranean vegetables, fruit, legumes, olive oil and fish; low intakes of four "non-Mediterranean" foods (soft drinks, butter, red meat and potatoes); and alcohol. If consumption of typical Mediterranean foods is in the 3rd tertile of the distribution, the person receives 1 point; all other intakes receive 0 points. If consumption of non-Mediterranean foods is in the first tertile of the distribution the person receives 1 point. Alcohol receives 1 point for intake up to 12 g/day; abstainers and persons who consume \>12 g/day receive 0. Possible scores range from 0 to 11.

    Time frame: Visit 2 (after 4 weeks from the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  30. Evaluation of adherence to healthy and sustainable dietary models: Greek Mediterranean Index

    To evaluate the adherence to and healthy and sustainable dietary, the Greek Mediterranean Index will be assessed with a nine-point score for the consumption of vegetables, legumes, fruit and nuts, cereal, fish, meat,dairy, alcohol, and lipids. Using the sex-specific median, a value of 0 will be given to participants whose consumption of vegetables, legumes, fruits and nuts, cereals, and fish is below the median consumption, while a value of 1 will be assigned in the opposite case. Study participants with a below-median consumption of meat and dairy products will be assigned a value of 1, whereas a value of 0 will be given to those with an above-median consumption. For ethanol, men consuming 10-50 g/day and women consuming 5-25 g/day will be given a value of 1. The score is categorized into three categories: low adherence, including individuals with a total score of 0 to 3 points; intermediate adherence, with a score of 4 to 5 points; and high adherence,with a score of 6 to 9 points.

    Time frame: Visit 2 (after 4 weeks from the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  31. Evaluation of adherence to healthy and sustainable dietary models: DASH Index

    Adherence to healthy dietary patterns will be assessed by the Dietary Approaches to Stop Hypertension (DASH) Index. The DASH Index is comprised of 8 components (7 food groups and one nutrient). The scoring system is based on quintile rankings; for intakes of fruit (includes fruit juice), vegetables (excludes potatoes), low-fat dairy products, whole grains, and nuts, seeds, and legumes, individuals receive a score from 1 (lowest quintile) to 5 (highest quintile). In contrast, individuals receive a score from 1 (highest quintile) to 5 (lowest quintile) for intakes of sodium, sugar-sweetened beverages, and red and processed meat. Men and women are classified into quintiles separately. Component scores are summed to a total DASH score that ranges from a minimum of 8 to a maximum of 40 points.

    Time frame: Visit 2 (after 4 weeks from the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  32. Evaluation of adherence to Mediterranean diet

    Adherence to Mediterranean Diet will be assessed through the MEDI-Lite questionnaire.

    Time frame: Visit 2 (after 4 weeks from the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  33. Nutritional and energy assessment: LARN

    Nutritional and energy requirements will be assessed considering the "Reference Intake Levels of Nutrients and Energy for the Italian Population for the Italian population" (LARN) recommendation using dietary records.

    Time frame: Visit 2 (after 4 weeks from the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  34. Nutritional and energy assessment: EPIC

    Nutritional and energy requirements will be assessed through the food frequency questionnaire European Prospective Investigation into Cancer and Nutrition (EPIC).

    Time frame: Visit 2 (after 4 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  35. Dietary intake assessment of plant bioactive compounds and dietary components related to gut microbiome

    (Poly)phenol intake will be estimated using a food database. The same methodology will serve to calculate the intake of other plant bioactive compounds and dietary components associated with the gut microbiome, by matching food frequency questionnaires, and the dietary records data with databases.

    Time frame: Visit 2 (after 4 weeks from the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  36. Lifestyle factors assessment: general information

    General information, such as age, sex, smoking habits, childbirth, breastfeeding, will be assessed through an enrollment questionnaire.

    Time frame: Visit 1 (beginning of the study), Visit 2 (4 weeks after the beginning of the study) Visit 3 (8 weeks after the beginning of the study), Visit 4 (16 weeks after the beginning of the study) and Visit 5 (24 weeks after the beginning of the study)

  37. Lifestyle factors assessment: sleep quality (PSQI)

    Assessing the contribution of sleep quality through the questionnaire Pittsburgh Sleep Quality Index (PSQI). Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme. A global sum of "5" or greater indicates a "poor" sleeper, while an overall sum of less than "5" indicates a "good" sleeper.

    Time frame: Visit 1 (beginning of the study), Visit 2 (4 weeks after the beginning of the study) Visit 3 (8 weeks after the beginning of the study), Visit 4 (16 weeks after the beginning of the study) and Visit 5 (24 weeks after the beginning of the study)

  38. Lifestyle factors assessment: sleep quality (ESS)

    Assessing the contribution of sleep quality through the questionnaire Epworth Sleepiness Scale (ESS). The test is a list of eight situations in which it is rate the tendency to become sleepy on a scale of 0 to 3: 0 (no chance of dozing), 1 (slight chance of dozing), 2 (moderate chance of dozing), and 3 (high chance of dozing). The total ESS score is based on a scale of 0 to 24 and can be interpreted as follows: 0-5 Lower Normal Daytime Sleepiness; 6-10 Higher Normal Daytime Sleepiness; 11-12 Mild Excessive Daytime Sleepiness; 13-15 Moderate Excessive Daytime Sleepiness; 16-24 Severe Excessive Daytime Sleepiness

    Time frame: Visit 1 (beginning of the study), Visit 2 (4 weeks after the beginning of the study) Visit 3 (8 weeks after the beginning of the study), Visit 4 (16 weeks after the beginning of the study) and Visit 5 (24 weeks after the beginning of the study)

  39. Lifestyle factors assessment: sleep quality (ISI)

    Assessing the contribution of sleep quality through the questionnaire Insomnia Severity Index (ISI).

    Time frame: Visit 1 (beginning of the study), Visit 2 (4 weeks after the beginning of the study) Visit 3 (8 weeks after the beginning of the study), Visit 4 (16 weeks after the beginning of the study) and Visit 5 (24 weeks after the beginning of the study)

  40. Lifestyle factors assessment: physical activity (IPAQ)

    Assessing the contribution of physical activity through the questionnaire International Physical Activity Questionnaire (IPAQ).

    Time frame: Visit 1 (beginning of the study), Visit 2 (4 weeks after the beginning of the study) Visit 3 (8 weeks after the beginning of the study), Visit 4 (16 weeks after the beginning of the study) and Visit 5 (24 weeks after the beginning of the study)

  41. Lifestyle factors assessment: state of health (BDI)

    Assessing the contribution of state of health through the questionnaire Beck's Depression Inventory (BDI).

    Time frame: Visit 1 (beginning of the study), Visit 2 (4 weeks after the beginning of the study) Visit 3 (8 weeks after the beginning of the study), Visit 4 (16 weeks after the beginning of the study) and Visit 5 (24 weeks after the beginning of the study)

  42. Lifestyle factors assessment: state of health (SF-36)

    Assessing the contribution of state of health through the questionnaire Short Form Health Survey 36 (SF-36).

    Time frame: Visit 1 (beginning of the study), Visit 2 (4 weeks after the beginning of the study) Visit 3 (8 weeks after the beginning of the study), Visit 4 (16 weeks after the beginning of the study) and Visit 5 (24 weeks after the beginning of the study)

  43. (Poly)phenol metabolites and changes in the prevalence of aggregate phenolic metabotypes

    True internal exposure to dietary (poly)phenols will be assessed by analysing the circulating metabolites of (poly)phenols in the plasma, urine, and faecal samples collected. Validated targeted ultra performance liquid chromatography method coupled with triple quadrupole mass spectrometry (UPLC-QqQ-MS/MS) and untargeted Ultra Performance Liquid Chromatography-Ion Mobility Spectrometry-High-Resolution Mass Spectrometry (UPLC-IMS-HRMS) methods will be used.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  44. Other plant bioactive metabolites

    True internal exposure to plant bioactive compounds will be assessed by analysing the circulating plant bioactive compounds (carotenoids, phytosterols, alkaloids (mainly purines and pyridines), thiosulfinates, and alkylresorcinols), in the plasma, urine, and faecal samples collected. Validated targeted ultra performance liquid chromatography method coupled with triple quadrupole mass spectrometry (UPLC-QqQ-MS/MS) and untargeted Ultra Performance Liquid Chromatography-Ion Mobility Spectrometry-High-Resolution Mass Spectrometry (UPLC-IMS-HRMS) methods will be used.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  45. Food/gut/host-derived metabolites

    Metabolites playing a role in the diet-gut microbiome-host interactions will be evaluated in plasma/urine/faeces samples using targeted ultra performance liquid chromatography method coupled with triple quadrupole mass spectrometry (UPLC-QqQ-MS/MS) and untargeted Ultra Performance Liquid Chromatography-Ion Mobility Spectrometry-High-Resolution Mass Spectrometry (UPLC-IMS-HRMS) methods. Main compounds to be targeted are short-chain fatty acids, L-carnitine, choline, phosphatidylcholine, trimethylamine, trimethylamine N-oxide, tryptophan and indole derivatives, phenylalanine and phenylacetate, tyrosine derivatives, 4-ethylphenylsulfate, p-cresol-sulfate, and primary and secondary bile acids.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  46. Biomarkers of food intake and of healthy dietary patterns

    Multiple metabolites associated with the consumption of food groups and foodstuffs will be analysed in urine samples and, in case, in plasma, using ultra performance liquid chromatography method coupled with triple quadrupole mass spectrometry (UPLC-QqQ-MS/MS) methods, to provide objective information on participants' diet. Moreover, a comprehensive panel of biomarkers related to healthy dietary patterns will be analysed in plasma/urine samples by using Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) methods procedures reported in literature.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  47. Untargeted metabolomics

    Urine/plasma/fecal samples will be subjected to untargeted Liquid Chromatography-Ion Mobility Spectrometry-Mass Spectrometry (LC-IMS-MS) metabolomics approach to assess potential differences among the metabolomes of individuals belonging to different aggregate phenolic metabotypes.

    Time frame: Visit 1 (at the beginning of the study), Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  48. Genetic differences

    Whole Exome Sequencing (WES) will be conducted using an exome-wide sequencing approach, using short reads, able to detect gene variability across the exome. Genomic DNA will be prepared from blood samples.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study)

  49. Gut microbiota composition

    Microbial profiling in faeces will be carried out by whole genome shotgun metagenomics analysis, for the sequencing of the entire bacterial DNA, aiming at greater accuracy and precision in taxonomic recognition and function inferences related to the microbiota.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  50. Oral microbiota composition

    Microbial profiling in saliva samples will be carried out by an internal transcribed spacer (ITS)-based method for cataloguing of bacterial communities at (sub)species level.

    Time frame: Visit 5 (after 24 weeks from the beginning of the study)

  51. Biomarkers of adipose tissue function

    A panel of biomarkers related to the adipose tissue function (adiponectin, leptin, and resistin) will be evaluated in plasma samples.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  52. Biomarkers of food intake regulation

    A panel of biomarkers related to food intake regulation (ghrelin, glucagon-like peptide 1, cholecystokinin, gastric inhibitory peptide) will be analysed in plasma samples.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  53. Biomarkers of cardiometabolic health: homeostasis model assessment beta-cell function

    Insulin resistance corrected by adiponection (HOMA-AD)

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  54. Biomarkers of cardiometabolic health: homeostasis model assessment beta-cell function

    HOMA2 will be used to determinate insulin sensitivity, insulin resistance, and beta cel function calculated by a computer model from C-peptide concentrations

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  55. Composite biomarkers: indices of systemic inflammation

    C-reactive protein to triglyceride-glucose index (CRP-TyG); Systemic Immune-Inflammation Index (SII); Systemic Inflammatory Response Index (SIRI); INFLA-score; Neutrophil-to-Lymphocyte Ratio (NLR); Neutrophil-to-HDL Cholesterol Ratio (NHR); and Neutrophil-to-Albumin Ratio (NAR).

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  56. Composite biomarkers: indices of metabolic dysfunction and insulin resistance

    Adipose Tissue Insulin Resistance index (Adipo-IR)

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  57. Composite biomarkers: lipid-relataed cardiovascular risk

    Atherogenic Index of Plasma (AIP)

    Time frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  58. Epigenetic analysis in blood samples

    DNA methylation analysis of the samples will be performed after sodium bisulfite treatment of the extracted DNA and analysed using the Illumina Infinium methylation 450k bead chip arrays (Illumina) on the NextSeq550 analyser (Illumina). These arrays cover between up to 860,000 humans genomic CpG sites, including 99% of RefSeq genes and 96% of CpG islands. The resulting methylated and unmethylated signal intensity data will be normalized according to Illumina's background correction method using the minfi package in R. All the samples will be examined for genome-wide methylation density, and those deviating from a bimodal distribution will be excluded.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  59. Epigenetic analysis in blood samples

    Telomerase analysis will be performed using qPCR to assess telomere length and telomerase activity strictly correlated with ageing.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  60. Transcriptomics and proteomics on lymphomonocytes and in vitro analysis of senescence-related gene expression and inflammaging

    Blood samples in tubes containing EDTA will be processed to obtain lymphomonocytes. Part of these will be stored at -80°C to allow subsequent transcriptomic or proteomic analysis, while the remainder will be stored in liquid nitrogen to allow in vitro use.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

  61. Taste phenotyping

    Taste system functionality is evaluated using the validated taste strips method. Participants identify the taste quality of filter paper strips impregnated with varying concentrations of taste solutions and rate the perceived taste intensity on a 10-point scale and the hedonic response on a 10-point hedonic scale.

    Time frame: Visit 5 (after 24 weeks from the beginning of the study)

  62. Whole-gut transit time

    Whole-gut transit time is assessed using the sunflower seed method: participants record the exact time elapsed between seed consumption and their first visual appearance in the stool.

    Time frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Feb 2027, 34 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 34 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Dec 2025 → Feb 2027 and completion Dec 2025 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Apr 4, 2024
StartActual
Apr 22, 2024
Primary completionEst.
Feb 28, 2027was Dec 2025
CompletionEst.
Feb 29, 2028was Dec 2025
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Feb 28, 2027
Nov 9, 2026
Study completion
Dec 31, 2025→Feb 29, 2028
Nov 9, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAt least one of the following risk factors: overweight or obese, central obesity (waist:hip ratio > 0.90 in males and > 0.85 in females or waist circumference ≥ 94 cm in males and ≥ 80 cm in females), hypertension (systolic BP > 130 or diastolic BP > 85 mm Hg), low high-density lipoprotein cholesterol levels (< 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in females), or elevated total cholesterol (≥ 200 mg/dL), low-density lipoprotein cholesterol (≥ 130 mg/dL (4.1 mmol/L)), triglyceride (> 150 mg/dL (1.7 mmol/L)), fasting glucose (> 100 mg/dL (5.6 mmol/L)) levels, or microalbuminuria (urinary albumin excretion ratio ≥ 20 μg/min or albumin:creatinine ratio ≥ 30 mg/g). In addition, it is necessary that the weight has been stable for at least 3 months. Similarly, concerning an ongoing therapy with medication or supplements, these must have been in use for at least 3 months.
Exclusion criteria
  • EditedBMI < 18.5 or > 3440.90 kg/m²
Nov 9, 2026
Secondary outcomes
10 added, 4 description edited
What changed in the outcomes
  • AddedBiomarkers of cardiometabolic health: homeostasis model assessment beta-cell functionTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedBiomarkers of cardiometabolic health: homeostasis model assessment beta-cell functionTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedComposite biomarkers: indices of systemic inflammationTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedComposite biomarkers: indices of metabolic dysfunction and insulin resistanceTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedComposite biomarkers: lipid-relataed cardiovascular riskTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedEpigenetic analysis in blood samplesTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedEpigenetic analysis in blood samplesTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedTranscriptomics and proteomics on lymphomonocytes and in vitro analysis of senescence-related gene expression and inflammagingTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • AddedTaste phenotypingTime frame: Visit 5 (after 24 weeks from the beginning of the study)
  • AddedWhole-gut transit timeTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
  • DescriptionBiomarkers of cardiometabolic health: hematochemical and urine analysis: how it is measured was reworded
  • DescriptionBiomarkers of cardiometabolic health: quantitative insulin-sensitivity check index: how it is measured was reworded
  • DescriptionGenetic differences: how it is measured was reworded
  • DescriptionGut microbiota composition: how it is measured was reworded
Nov 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Azienda Ospedaliero-Universitaria di Parma · Parma, ItalyContact r•••@unipr.it · •••3307→a•••@unipr.it · •••3321
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Dec 31, 2025→Feb 28, 2027
    Study completion Dec 31, 2025→Feb 29, 2028
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAt least one of the following risk factors: overweight or obese, central obesity (waist:hip ratio > 0.90 in males and > 0.85 in females or waist circumference ≥ 94 cm in males and ≥ 80 cm in females), hypertension (systolic BP > 130 or diastolic BP > 85 mm Hg), low high-density lipoprotein cholesterol levels (< 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in females), or elevated total cholesterol (≥ 200 mg/dL), low-density lipoprotein cholesterol (≥ 130 mg/dL (4.1 mmol/L)), triglyceride (> 150 mg/dL (1.7 mmol/L)), fasting glucose (> 100 mg/dL (5.6 mmol/L)) levels, or microalbuminuria (urinary albumin excretion ratio ≥ 20 μg/min or albumin:creatinine ratio ≥ 30 mg/g). In addition, it is necessary that the weight has been stable for at least 3 months. Similarly, concerning an ongoing therapy with medication or supplements, these must have been in use for at least 3 months.
    Exclusion criteria
    • EditedBMI < 18.5 or > 3440.90 kg/m²
    Secondary outcomes 10 added, 4 description edited
    What changed in the outcomes
    • AddedBiomarkers of cardiometabolic health: homeostasis model assessment beta-cell functionTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedBiomarkers of cardiometabolic health: homeostasis model assessment beta-cell functionTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedComposite biomarkers: indices of systemic inflammationTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedComposite biomarkers: indices of metabolic dysfunction and insulin resistanceTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedComposite biomarkers: lipid-relataed cardiovascular riskTime frame: Visit 3 (after 8 weeks from the beginning of the study), Visit 4 (after 16 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedEpigenetic analysis in blood samplesTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedEpigenetic analysis in blood samplesTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedTranscriptomics and proteomics on lymphomonocytes and in vitro analysis of senescence-related gene expression and inflammagingTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • AddedTaste phenotypingTime frame: Visit 5 (after 24 weeks from the beginning of the study)
    • AddedWhole-gut transit timeTime frame: Visit 3 (after 8 weeks from the beginning of the study) and Visit 5 (after 24 weeks from the beginning of the study)
    • DescriptionBiomarkers of cardiometabolic health: hematochemical and urine analysis: how it is measured was reworded
    • DescriptionBiomarkers of cardiometabolic health: quantitative insulin-sensitivity check index: how it is measured was reworded
    • DescriptionGenetic differences: how it is measured was reworded
    • DescriptionGut microbiota composition: how it is measured was reworded
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Azienda Ospedaliero-Universitaria di Parma · Parma, ItalyContact r•••@unipr.it · •••3307→a•••@unipr.it · •••3321
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06347094
Lead sponsor
University of Parma
Collaborators
Azienda Ospedaliero-Universitaria di Parma, University of Milan, Foundation for Liver Research, National Research Council, Spain
Responsible party
Pedro M. Mena Parreño (PhD, University of Parma) — Principal investigator
First posted
Apr 4, 2024
Start date
Apr 22, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Pedro M Mena Parreño, PhD
Contact
pedromiguel.menaparreno@unipr.it
+39 0521 903970
Maria Sole Morandini, MSc
Contact
mariasole.morandini@unipr.it
+39 0521902043
Pedro M Mena Parreño, PhD
principal investigator · University of Parma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion